Christian S. Schade

CHRISTIAN S. SCHADE has been a director since 2006.

Chris was the president and chief executive officer of Halda Therapeutics, a private biotechnology company developing a novel class of cancer therapies until its sale to Johnson & Johnson in December 2025. Prior to Halda, Chris was a Growth Partner at Flagship Pioneering where he worked with leaders at Flagship-founded biotech companies on strategy, financing, and business development. Prior to joining Flagship, Chris served as the president and chief executive officer of Aprea Therapeutics, a publicly traded, clinical-stage biopharmaceutical company from 2016 to 2022. Previous to this role, Chris assumed a variety of senior leadership roles including: chief executive officer of Novira Therapeutics, Inc.; executive vice president and chief financial officer of Omthera Pharmaceuticals, Inc.; executive vice president and chief financial officer at NRG Energy; and senior vice president for administration and chief financial officer at Medarex Inc.

Prior to his career in the biopharma industry, Chris was a managing director at Merrill Lynch, leading the European Corporate Funding Group and held various corporate finance and capital markets roles in New York and London for both Merrill Lynch and JP Morgan.

Chris received an A.B. degree from Princeton University and received an MBA from the Wharton School at the University of Pennsylvania.